Fig. 3
From: Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
Comparison of PML patients and respective control groups. a HIV PML patients compared with HIV patients without PML regrading CSF cell count, CSF lactate, CSF protein and Qalbumin. b MS/NTZ patients compared with MS control group. CSF: cerebrospinal fluid, HIV: human immunodeficiency virus, MS: multiple sclerosis, NTZ: natalizumab, PML: progressive multifocal leukoencephalopathy. Data is presented as mean ± standard deviation. Levels of significance: ****p < 0.0001, **p < 0.01, *p < 0.05, ns: not significant, two-tailed p-value, Mann–Whitney-test with comparison of median values was applied